Skip to main content
Equibles
QTRX logo

QTRX · Quanterix Corp

Track QTRX — free

Use QTRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about QTRX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.59 -0.27 (-9.44%) At close · Aug 14
Market Cap
$122.49M
Shares
47.29M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.59 Open$2.86 Day$2.55–2.86 52W close$2.42–8.06 Avg vol 30d700K Short int4.5M · 9.5% float · 9.1d Short vol51% Last earningsAug 10, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Nov 14, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −46%
      below
      Price vs 50-day avg −28%
      below
      RSI (14) 36
      neutral
      MACD trend Negative
      52-week position 3%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −33%
      trailing
      6-month return −54%
      trailing
      YTD return −59%
      this year
      Relative strength −68%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $4 › 200d $5 — 200d above 50d
      Institutional flow Accumulating
      +3% holders QoQ · +38 funds added
      Insider flow Accumulating
      Net +$286.4K over 90 days · 0% sells
      Short interest Rising
      9.53% of float · ▲ +3.9% MoM · 9.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      132 holders — mid 3-yr range
      Squeeze score 72
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +65%
      Y/Y
      Gross margin 173%
      contracting
      EPS growth −151%
      Y/Y
      Free cash flow $-79.8M
      Balance sheet $14.6M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 89%
      annualized · 1-yr
      Max drawdown −70%
      past year
      ATR 14.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 1 of last 2
      Latest guidance · from the 8-K filed Aug 10, 2026
      2026
      Revenues $142M – $148M
      prior FY $138.9M midpoint +4.4% Y/Y
      Non-GAAP gross margins Non-GAAP 48% – 50%
      2026 year-end
      2026 year-end cash balance $80M
      Prior guidance period ended · from the 8-K filed Nov 10, 2025
      Revenues · 2025 $130M – $135M
      GAAP gross margin · 2025 45% – 47%
      Adjusted gross margin (non-GAAP) · 2025 45% – 47%
      Adjusted cash usage · 2025 $34M – $38M
      Cash, cash equivalents, marketable securities, and restricted ca · end of 2025 $120M
      Total Cash Usage · 2025 $170M – $174M
      Exit Cash · 2025 $120M
      Guided vs delivered · last 2 settled
      Revenues 2025
      guided $130M – $135M
      $138.9M Beat +4.8%
      Full year revenue full year 2024
      guided $139M – $144M
      $137.42M Miss −2.9%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −46% Bearish
      Price vs 50-day avg
      −28% Bearish
      RSI (14)
      36 Neutral
      MACD trend
      Negative Bearish
      52-week position
      3% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $4 › 200d $5 — 200d above 50d
      Institutional flow Accumulating
      +3% holders QoQ · +38 funds added
      Insider flow Accumulating
      Net +$286.4K over 90 days · 0% sells
      Short interest Rising
      9.53% of float · ▲ +3.9% MoM · 9.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      132 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $2 Now $3 · 3% Range high $8
      vs 200-day avg -46% vs 50-day avg -28%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted cash usage (non-GAAP) non-GAAP -$3.99M Three Months Ended June 30, 2026 —
      Adjusted EBITDA (non-GAAP) non-GAAP -$9.99M Three Months Ended June 30, 2026 —
      Adjusted EBITDA margin (non-GAAP) non-GAAP -28.6% Six Months Ended June 30, 2026 —
      Adjusted gross profit (non-GAAP) non-GAAP $15.76M Three Months Ended June 30, 2026 —
      Adjusted loss from operations (non-GAAP) non-GAAP -$15.99M Three Months Ended June 30, 2026 —
      Adjusted total operating expenses (non-GAAP) non-GAAP $31.75M Three Months Ended June 30, 2026 —
      Cash Balance $97M Q2'26 —
      CMS reimbursement rate for LucentAD Test $897 Q2'26 —
      CMS reimbursement rate for LucentAD Complete test $897 Full Year 2025 —
      Cost savings related to Akoya transaction $74M Full Year 2025 —
      Installed instruments 1,439 Full Year 2025 —
      Integration milestones complete 94% Full Year 2025 —
      New assays launched 13 Full Year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      QTRX
      Quanterix Corp
      this stock
      		$122.49M -59.3% +64.5% — 9.5%
      ABT
      Abbott Laboratories
      		 $193.78B -11.2% +5.7% 31.2 1.3%
      SYK
      Stryker Corp
      		 $130.11B -3.5% +11.2% 35.2 2.2%
      MDT
      Medtronic plc
      		 $116.83B -5.0% +8.4% 24.5 1.4%
      BSX
      Boston Scientific Corp
      		 $75.11B -45.6% +12.5% 21.0 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      132
      % held
      62.9%
      Net QoQ
      -6.8M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      133
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      4.5M
      Days to cover
      9.1d
      Change
      +167.7K sh
      View
      Short Volume
      Short vol %
      51%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      21.9K
      Value
      $93.8K
      As of
      Jul 7, 2026
      View
      Off-Exchange
      Off-exchange %
      36.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$286.4K
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $138.9M
      Net income (FY)
      $-107.2M
      EPS diluted
      $-2.51
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $378.1K
      Shares
      20.9K
      Filed
      Jun 12, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View
      Investor Relations
      Latest news
      Quanterix Names Jim Gute Chief Co…
      Published
      Aug 10, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      QTRX -35.7% -33.0% -54.3% -25.6% -59.3%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -36.1% -37.4% -68.1% -29.5% -73.1%
      Key facts CIK 1503274 CUSIP 74766Q101 13F (30d) 130 filings 125 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)